How to access Austedo for Huntington's chorea or tardive dyskinesia from Dubai: 2026 pathway via DHA neurology services and community pharmacy supply
*Clinically reviewed by Mohammad Ali, MD (US-trained physician, Chief AI Officer, Reserve Meds). Last reviewed 2026-05-20.
Dubai's adult movement disorders care concentrates at American Hospital Dubai neurology, Mediclinic City Hospital and Mediclinic Parkview neurology, King's College Hospital London Dubai neurology, Saudi German Hospital Dubai neurology, NMC Specialty neurology, the Dr Sulaiman Al Habib network, the Aster network, and the German Neuroscience Centre Dubai. For the tardive dyskinesia subset, American Hospital Dubai psychiatry, Priory Wellbeing Centre Dubai, and Mediclinic City Hospital psychiatry are the routine prescribing partners. For complex Huntington's cases requiring detailed movement disorders evaluation, cross-emirate referral to Cleveland Clinic Abu Dhabi's movement disorders programme is the established pattern. Dubai Health Authority (DHA) Pharmaceutical Affairs coordinates Dubai-emirate dispensing under the federal Emirates Drug Establishment registration framework. Austedo (deutetrabenazine; once-daily extended-release variant Austedo XR) is the selective VMAT2 inhibitor from Teva Pharmaceuticals, approved by the FDA in 2017 for chorea associated with Huntington's disease in adults and for tardive dyskinesia in adults. For a Dubai-resident adult patient with confirmed Huntington's chorea or moderate-to-severe tardive dyskinesia, the operational question is which prescribing centre fits the case, how the EDE-registered or named-patient supply reaches the dispensing pharmacy, what the insurance pre-authorisation conversation looks like (Saada/Enaya for nationals; DHA employer plans and commercial cover for residents), what the structured depression and suicidality monitoring schedule looks like (the boxed warning for Huntington's), and how the multi-year treatment course settles into a Dubai family's life.
This page explains how the pathway works in 2026 for a Dubai-resident patient: who qualifies, where the neurologist or psychiatrist conversation happens, where the prescription is written and filled, what the realistic out-of-pocket exposure band is in AED, what to monitor on therapy, and how the longer-term treatment course fits into a Dubai family's life.
Why Austedo, and why now
Austedo is deutetrabenazine, a selective VMAT2 inhibitor. VMAT2 packages dopamine and other monoamines into synaptic vesicles; inhibiting it reduces presynaptic dopamine stores. In hyperkinetic movement disorders driven by excess dopaminergic signalling, this is therapeutically beneficial. Developed by Auspex (acquired by Teva 2015), a deuterated analogue of tetrabenazine with smoother PK, twice-daily or once-daily Austedo XR dosing, and a lower depression-adverse-event signal than tetrabenazine.
FDA: Huntington's chorea April 2017, tardive dyskinesia August 2017, Austedo XR February 2023. Pivotal trials First-HD, ARM-TD, AIM-TD.
For a Dubai patient with confirmed Huntington's chorea, or with moderate-to-severe TD on a stable underlying psychiatric regimen, Austedo is the operational answer. The boxed warning for depression and suicidality in Huntington's patients is the central safety consideration.
What Austedo is, in plain language
Oral tablet, immediate-release twice daily or Austedo XR once daily. Tablets in 6, 9, 12 mg (Austedo) and 6, 12, 18, 24, 30, 36, 42, 48 mg (Austedo XR). Taken with food. Room temperature storage.
Titration: 6 mg once daily week 1, increase by 6 mg/day weekly, reach maintenance over 6 to 9 weeks. Maintenance 12 to 48 mg/day. Cap 48 mg/day standard; 36 mg/day for CYP2D6 poor metabolisers or concurrent strong CYP2D6 inhibitors.
Eligibility at a Dubai neurology or psychiatry clinic
For Huntington's chorea:
1. Confirmed Huntington's by HTT CAG repeat sizing (American Hospital Dubai, Mediclinic City Hospital, Saudi German Hospital Dubai, Mediclinic Parkview, and Al Zahra Hospital Dubai). 2. Clinically significant chorea on UHDRS Total Maximal Chorea score (8 or greater). 3. Baseline depression screening (PHQ-9). Active suicidal ideation or untreated severe depression is a contraindication. 4. Baseline suicidality risk assessment (C-SSRS). 5. Baseline cognitive and functional assessment.
For tardive dyskinesia:
1. Confirmed TD by neurologist or psychiatrist with documented chronic dopamine-blocker exposure and characteristic movements on AIMS or DISCUS. 2. Baseline AIMS or DISCUS score. 3. Stable underlying psychiatric or gastrointestinal condition. 4. Baseline PHQ-9.
For both: CYP2D6 genotype where available; MAOI contraindication; concurrent reserpine/tetrabenazine/valbenazine contraindication; baseline ECG where indicated; pregnancy and lactation screen; hepatic function review.
A Dubai patient should arrive with the HTT CAG repeat report (Huntington's), UHDRS chorea or AIMS/DISCUS score (TD), PHQ-9 and C-SSRS baseline, complete medication history, baseline ECG where indicated, and insurance documentation.
Dubai prescribing and dispense picture, plainly
Austedo registration status at the federal Emirates Drug Establishment governs Dubai-emirate availability; DHA Pharmaceutical Affairs coordinates emirate-level dispensing. [VERIFY: current EDE Austedo registration status at point of dispense.] Where Austedo is registered and commercially supplied through Teva's regional distributor network, in-country dispensing applies through DHA-licensed pharmacies. Where in-country registration is absent, a named-patient pathway can apply for documented physician-initiated prescriptions referencing FDA-approved indications.
1. Prescribing physician: a board-certified Dubai neurologist (movement disorders subspecialty preferred for Huntington's) or psychiatrist with movement-disorder experience (typical for TD). Major Dubai prescribing centres: - Adult neurology / movement disorders: American Hospital Dubai neurology, Mediclinic City Hospital and Mediclinic Parkview neurology, King's College Hospital London Dubai neurology, Saudi German Hospital Dubai neurology, NMC Specialty neurology, the Dr Sulaiman Al Habib network, the Aster network, and the German Neuroscience Centre Dubai. Public sector neurology at Rashid and Latifa Hospitals serves Emirati nationals. - Tardive dyskinesia / psychiatric-comorbid: American Hospital Dubai psychiatry, Priory Wellbeing Centre Dubai, Mediclinic City Hospital psychiatry. - Complex Huntington's cases: cross-emirate referral to Cleveland Clinic Abu Dhabi movement disorders programme. 2. Diagnostic workup: HTT CAG repeat sizing for Huntington's cases through American Hospital Dubai or Mediclinic City clinical genetics services, cross-emirate referral to Cleveland Clinic Abu Dhabi clinical genetics, or international laboratories. UHDRS chorea scoring at the prescribing centre. For TD, AIMS or DISCUS scoring with documented chronic dopamine-blocker exposure history. 3. Insurance pre-authorisation: Saada (for Emirati nationals registered in Dubai) and Enaya (Dubai government employee health plan) cover VMAT2 inhibitor therapy for documented Huntington's chorea or moderate-to-severe TD with clinical justification. DHA-licensed employer plans and commercial covers (Oman Insurance, AXA Gulf, MetLife, Cigna, NEXtCARE, Bupa Global) vary; clinical rationale letter typically required documenting diagnosis confirmation and baseline depression screening. Pre-authorisation typically takes 7 to 21 days. 4. Pharmacy dispense: 30-day supply at the prescribing centre's outpatient pharmacy or a DHA-licensed specialty pharmacy with the VMAT2 inhibitor inventory line. Teva's MENA commercial distributor network handles Austedo-branded supply where in-country registration applies. 5. Refill cycle: monthly. Documentation of ongoing chorea or AIMS response, depression and suicidality screening, and tolerability.
The 2026 pathway, step by step
Week 0 to 3: Documentation pack with treating neurologist's or psychiatrist's office at American Hospital Dubai, Mediclinic City, or chosen prescribing centre. HTT CAG repeat sizing (Huntington's), AIMS or DISCUS with dopamine-blocker exposure history (TD), PHQ-9 and C-SSRS, medication history, baseline ECG, insurance documentation.
Week 3 to 5: Insurance pre-authorisation review.
Week 5 to 6: First dispense. Starting dose 6 mg once daily for one week.
Week 6 to 14: Titration phase. Weekly clinical contact for PHQ-9, tolerability, extrapyramidal symptom monitoring.
Month 3 onwards: Maintenance dosing. Monthly refill. Monthly depression and suicidality screening for Huntington's; baseline-anchored at each visit for TD.
Ongoing: Maintenance, monthly refill, structured monitoring.
Cost expectation in AED
US Austedo list price (2026) approximately USD 8,000 to USD 10,000 per 30-day supply; annual cost USD 100,000 to USD 120,000 at list price.
At 2026 cross rates, a 30-day Austedo supply at USD 9,000 is approximately AED 33,000, annual cost at USD 110,000 is approximately AED 404,000.
For Emirati nationals registered in Dubai with Saada coverage, VMAT2 inhibitor therapy is typically covered with documented diagnosis. Enaya for Dubai government employees follows the same pattern. Commercial covers and DHA-licensed employer plans vary; out-of-pocket exposure for a covered patient is generally a co-payment band.
Monitoring on therapy
- Depression and suicidality (boxed warning for Huntington's): PHQ-9 at baseline, weekly during titration, monthly during maintenance. C-SSRS at baseline and at any mood change. - Extrapyramidal symptoms: clinical assessment at each visit. - Somnolence: clinical assessment particularly during titration. Driving restricted during titration. - ECG: at baseline and at maintenance dose where indicated. - Chorea or AIMS score: at baseline and at 4 to 6 week intervals. - CYP2D6 status: genotyping where indicated.
Religious, ethical, and family-logistics framing
Austedo is an oral small molecule with no animal-source material. Halal acceptability is not in question.
For Huntington's, autosomal-dominant genetic implications; 50 percent risk to each child; structured genetic counselling for siblings, children, and extended family through American Hospital Dubai or Mediclinic City clinical genetics, cross-emirate referral to Cleveland Clinic Abu Dhabi clinical genetics, or international counselling services.
For tardive dyskinesia, the patient carries a primary psychiatric or gastrointestinal diagnosis. Dubai psychiatry services at American Hospital, Priory Wellbeing Centre, and Mediclinic City handle the cases with discretion as standard practice; medical record confidential.
For women of reproductive potential, effective contraception required during treatment.
Austedo XR once-daily simplifies adherence.
When Austedo is not the right call
Not appropriate for active suicidal ideation or untreated severe depression, concurrent MAOI (or within 14 days), concurrent reserpine/tetrabenazine/valbenazine, pregnant women without specialist counsel, severe hepatic impairment without dose adjustment, or parkinsonian or akinetic-rigid syndromes.
Alternatives for Huntington's chorea in 2026: tetrabenazine, amantadine, pridopidine (clinical-trial access), atypical antipsychotics off-label, multidisciplinary supportive care.
Alternatives for TD in 2026: valbenazine (Ingrezza), discontinuation or switching of the offending dopamine-blocker, clozapine substitution, botulinum toxin injection.
Reserve Meds does not promote one VMAT2 inhibitor over another. The clinical decision sits with the prescribing physician.
What Reserve Meds does on this case
We are a US-based concierge coordinator. We are not the prescriber and not the dispensing pharmacy. On a Dubai Austedo case we build the documentation pack, submit first-review requests to American Hospital Dubai, Mediclinic City, or chosen prescribing centre, coordinate HTT CAG repeat sizing for Huntington's cases through the chosen clinical genetics service or cross-emirate referral, coordinate the insurance pre-authorisation conversation, set up the first 30-day dispense at a DHA-licensed pharmacy, organise the structured depression and suicidality monitoring schedule, and stay with the case through the first year. Clinical decisions remain with your treating neurologist or psychiatrist.
Composite case examples; no individual patient is depicted. This content is for general information and does not constitute medical advice. Reserve Meds is a US-based concierge coordinator; we are not the prescriber and not the dispensing pharmacy. Clinical decisions remain with your treating neurologist or psychiatrist.
Clinical and regulatory review: Mohammad Ali, MD (US-trained physician, Chief AI Officer, Reserve Meds). Last medically reviewed: 2026-05-20.